Ramez Eskander, MD
Gynecologic Oncology · Encinitas, CANPI 1144486929
Payments from drug & device makers
Across 600 payments — averaging $13,611 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6.4M
- Clovis Oncology, Inc.$393K
- Eli Lilly$235K
- Astrazeneca UK Limited$221K
- AstraZeneca$171K
- Novocure Inc.$125K
- plus $654K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 138 | $6,368,548 |
| Clovis Oncology, Inc. | 33 | $392,657 |
| Eli Lilly | 4 | $235,111 |
| Astrazeneca UK Limited | 15 | $221,079 |
| AstraZeneca | 116 | $171,101 |
| Novocure Inc. | 9 | $124,729 |
| F. Hoffmann-la Roche AG | 14 | $110,919 |
| AbbVie | 22 | $100,272 |
| Eisai Inc. | 61 | $73,271 |
| Genmab U.S., Inc. | 16 | $71,953 |
| GSK | 40 | $56,470 |
| Epizyme, Inc. | 1 | $50,000 |
| Roche Products Limited | 1 | $28,405 |
| Genentech, Inc. | 1 | $27,820 |
| Regeneron | 20 | $22,045 |
| Seagen Inc. | 19 | $18,903 |
| Daiichi Sankyo Inc. | 12 | $15,869 |
| Myriad Genetic Laboratories, Inc. | 17 | $15,332 |
| Pfizer | 6 | $10,716 |
| Immunogen, Inc. | 8 | $6,852 |
| Corcept Therapeutics | 6 | $5,484 |
| Biontech SE | 6 | $5,437 |
| Beone Medicines USA, Inc. | 4 | $5,200 |
| Gilead | 6 | $5,170 |
| Beigene USA, Inc. | 2 | $3,900 |
| Eisai CO., LTD. | 1 | $3,160 |
| Incyte Corporation | 2 | $3,148 |
| Aadi Bioscience, Inc. | 2 | $3,106 |
| Macrogenics, Inc. | 1 | $3,000 |
| Novocure GmbH | 1 | $2,400 |
| Tesaro, Inc. | 7 | $2,154 |
| Novartis | 1 | $1,722 |
| Intuitive Surgical | 2 | $337 |
| Foundation Medicine, Inc. | 1 | $229 |
| Karyopharm Therapeutics Inc. | 2 | $136 |
| Genentech USA, Inc. | 1 | $127 |
| Amgen | 1 | $17 |
| Medical Device Business Services, Inc. | 1 | $13 |
How this compares
$8,166,791 in reported general payments places this provider in the 95th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Encinitas
- John ChanSan Francisco$3.1M
- Krishnansu TewariOrange$3M
- Dana ChaseLos Angeles$2.8M
- Edwin AlvarezSacramento$1.4M
- Philip DisaiaOrange$1.2M
- Alberto MendivilNewport Beach$1.2M
- Fabio CappucciniOrange$1.1M
- Michael McHalela Jolla$979K
- Lee-May ChenSan Francisco$930K
- Elisabeth DiverPalo Alto$916K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.